Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    22293030 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed
Has Results
Ezetimibe/Simvastatin (10 mg/40 mg) vs. the Doubling of Atorvastatin in High Risk Participants (MK-0653A-134 AM1)(COMPLETED)
Condition: Hypercholesterolemia
Interventions: Drug: ezetimibe/simvastatin 10/40;   Drug: atorvastatin 40 mg;   Drug: atorvastatin 20 mg

Indicates status has not been verified in more than two years